A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recogn
about
Top-down, Bottom-up and Middle-out Strategies for Drug Cardiac Safety Assessment via Modeling and SimulationsRecent Advances in Development and Application of Physiologically-Based Pharmacokinetic (PBPK) Models: a Transition from Academic Curiosity to Regulatory AcceptancePredicting Drug Extraction in the Human Gut Wall: Assessing Contributions from Drug Metabolizing Enzymes and Transporter Proteins using Preclinical ModelsTowards quantitation of the effects of renal impairment and probenecid inhibition on kidney uptake and efflux transporters, using physiologically based pharmacokinetic modelling and simulationsPhysiologically Based Pharmacokinetic Predictions of Tramadol Exposure Throughout Pediatric Life: an Analysis of the Different Clearance Contributors with Emphasis on CYP2D6 Maturation.Physiologically Based Pharmacokinetic (PBPK) Modeling and Simulation Approaches: A Systematic Review of Published Models, Applications, and Model VerificationEvaluation of a High-Throughput Peptide Reactivity Format Assay for Assessment of the Skin Sensitization Potential of ChemicalsBayesian Population Physiologically-Based Pharmacokinetic (PBPK) Approach for a Physiologically Realistic Characterization of Interindividual Variability in Clinically Relevant PopulationsCombining the 'bottom up' and 'top down' approaches in pharmacokinetic modelling: fitting PBPK models to observed clinical dataThe Use of In Vitro Data and Physiologically-Based Pharmacokinetic Modeling to Predict Drug Metabolite Exposure: Desipramine Exposure in Cytochrome P4502D6 Extensive and Poor Metabolizers Following Administration of Imipramine.Human plasma metabolic profiles of benzydamine, a flavin-containing monooxygenase probe substrate, simulated with pharmacokinetic data from control and humanized-liver mice.Determination of the most influential sources of variability in tacrolimus trough blood concentrations in adult liver transplant recipients: a bottom-up approachApplication of Physiologically-Based Pharmacokinetic Modeling for the Prediction of Tofacitinib Exposure in JapaneseTips and traps analyzing pediatric PK data.Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance.Simulation of monoclonal antibody pharmacokinetics in humans using a minimal physiologically based model.What is the right dose for children?Alternative (non-animal) methods for cosmetics testing: current status and future prospects-2010.The simcyp population based simulator: architecture, implementation, and quality assurance.Applications of linking PBPK and PD models to predict the impact of genotypic variability, formulation differences, differences in target binding capacity and target site drug concentrations on drug responses and variabilityPhysiologically based pharmacokinetic modeling and simulation in pediatric drug developmentExpansion of a PBPK model to predict disposition in pregnant women of drugs cleared via multiple CYP enzymes, including CYP2B6, CYP2C9 and CYP2C19Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update.Modeling the Human Kinetic Adjustment Factor for Inhaled Volatile Organic Chemicals: Whole Population Approach versus Distinct Subpopulation ApproachGenerating Virtual Patients by Multivariate and Discrete Re-Sampling TechniquesA probabilistic model of human variability in physiology for future application to dose reconstruction and QIVIVE.Parsing interindividual drug variability: an emerging role for systems pharmacology.Evaluating a physiologically based pharmacokinetic model for predicting the pharmacokinetics of midazolam in Chinese after oral administration.Modeling interindividual variability in physiologically based pharmacokinetics and its link to mechanistic covariate modeling.A PBPK Model to Predict Disposition of CYP3A-Metabolized Drugs in Pregnant Women: Verification and Discerning the Site of CYP3A Induction.A physiologically based pharmacokinetic model to predict disposition of CYP2D6 and CYP1A2 metabolized drugs in pregnant women.Predicted metabolic drug clearance with increasing adult age.Efficient Generation and Selection of Virtual Populations in Quantitative Systems Pharmacology Models.Dose selection based on physiologically based pharmacokinetic (PBPK) approaches.Prediction of Drug-Drug Interactions Arising from CYP3A induction Using a Physiologically Based Dynamic ModelPhysiologically based pharmacokinetic modelling of drug penetration across the blood-brain barrier--towards a mechanistic IVIVE-based approachCharacterizing the Developmental Trajectory of Sirolimus Clearance in Neonates and InfantsPopulation-based mechanistic prediction of oral drug absorptionCYP2B6 pharmacogenetics-based in vitro-in vivo extrapolation of efavirenz clearance by physiologically based pharmacokinetic modeling.More Power to OATP1B1: An Evaluation of Sample Size in Pharmacogenetic Studies Using a Rosuvastatin PBPK Model for Intestinal, Hepatic, and Renal Transporter-Mediated Clearances.
P2860
Q26739743-07903105-28B7-4340-B064-8881EBA3902BQ26745824-564DCAE5-9968-401C-94D7-CB7B8A14CE1BQ26764739-DFB4004C-A924-4E73-9C55-D382CB58A02FQ27020967-3359A664-C989-46DE-90A4-B667A82E5862Q27312881-2F2C25AE-713B-45D2-8180-9F8E47DB984FQ28088352-3052DD72-3C00-4FCF-BC05-913A2965097AQ28389536-8D4042BA-1354-4EDB-8DB4-16C62AE51AEFQ28550022-08F680D1-ADB2-4BAA-8A83-F8C8E7262F1CQ30666721-05EA522F-8FE3-4BCA-B51C-EFBF614E782AQ31116232-0321B7AA-1B67-4AAB-AF2E-6732A7F7878CQ31158659-77D98B41-1DCD-47C6-92B4-BE92A88CC164Q33574176-AFDA0E7D-5A08-4823-BA5C-1F2B48943C45Q33703161-4009F37E-5156-4258-8C52-D8183273D9CDQ33820152-18AB6276-D4D1-4062-A110-DD332641C2E7Q34075909-67CF2271-C8A4-404D-9E76-97E860E1685CQ34099756-72C66644-7E02-46C2-82A3-059E25069587Q34180493-AEB9F7E1-C277-4CB9-A0AF-E1D2656B0A80Q34181630-1125BE13-407F-4B66-8BD3-5C1BEF4C2F37Q34502721-10259711-DB7C-40BB-8D5D-0E80A4820065Q34574831-0281C2B6-A63A-4AFB-8826-5B55B9C643F8Q34658074-C432F9B5-2B39-4DF9-B52A-544A88DC8F4DQ35211432-68AEA4C1-F228-4F9A-AAE7-50CFB80A479BQ35771833-CE2BC5CA-ECBC-4028-BB07-BCEBEC1853FEQ35864881-A91A0556-61B8-4954-907F-2C0FAD7ECB86Q36080108-55E2CB0B-DBC6-4A65-AA07-9BB5141BE30EQ36146247-C16976C9-F7F5-4905-B6BB-569F15EF051CQ36417380-8903C3C6-66A4-495B-9296-08F6E98CFC06Q36579268-EB5F3B0D-02B6-470B-9DCE-9AAE488A44BFQ36702459-E01D5C41-2F6C-4D57-8259-A1045AE15EB5Q36712344-CE7C517C-36AD-4F25-AAB3-B1636D69AA18Q36717181-629D0457-EDBC-4174-85FC-4DCB1EBB4595Q36729942-7BF317AE-04C9-4D7D-856F-573D86FFCC48Q36734135-CBF4416E-9F6E-45BB-9CC6-25FA90384A35Q36910606-4EEBC4BD-3F28-4B67-8946-41B38DD780CDQ36947718-AB4A5D74-A0D2-4D76-85F7-63F3F817D2B0Q37207750-F7FFE9DB-5C34-4A88-B2CC-99CDE3DFB9F8Q37208505-693CBF36-DB35-4E40-BE95-8A0E9F691FD5Q37214520-4C8F5388-29E6-4C84-9520-E0FB67A5B8ACQ37325589-84CE8F1D-D5E7-46C5-AA6B-67FD77707F65Q37394474-423EC674-58CD-4D88-B967-F465AC9A25D1
P2860
A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down' recogn
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
A framework for assessing inte ...... ottom-up' vs 'top-down' recogn
@en
A framework for assessing inte ...... ottom-up' vs 'top-down' recogn
@nl
type
label
A framework for assessing inte ...... ottom-up' vs 'top-down' recogn
@en
A framework for assessing inte ...... ottom-up' vs 'top-down' recogn
@nl
prefLabel
A framework for assessing inte ...... ottom-up' vs 'top-down' recogn
@en
A framework for assessing inte ...... ottom-up' vs 'top-down' recogn
@nl
P2093
P356
P1476
A framework for assessing inte ...... ottom-up' vs 'top-down' recogn
@en
P2093
Amin Rostami-Hodjegan
Gemma L Dickinson
Masoud Jamei
P356
10.2133/DMPK.24.53
P577
2009-01-01T00:00:00Z